Rexahn Pharmaceuticals, Inc. (RNN) Scheduled to Post Quarterly Earnings on Monday
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) is scheduled to be announcing its Q3 2017 earnings results on Monday, November 6th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
Shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT RNN) opened at $1.91 on Friday. Rexahn Pharmaceuticals, Inc. has a twelve month low of $0.38 and a twelve month high of $7.10.
WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/rexahn-pharmaceuticals-inc-rnn-scheduled-to-post-quarterly-earnings-on-monday/1677040.html.
A number of analysts have weighed in on RNN shares. HC Wainwright set a $20.00 target price on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 11th. ValuEngine upgraded Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday. Seaport Global Securities reiterated a “buy” rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research lowered Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Finally, Ifs Securities reiterated an “outperform” rating on shares of Rexahn Pharmaceuticals in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.85.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.